Two years after her lung cancer diagnosis in 2019, Dan Wu first came to D. Ross Camidge, MD, PhD, at the University of Colorado Cancer Center for a second opinion.
“Dr. Camidge saved my life,” Wu said.
Patient Care Lung Cancer Oncology
Two years after her lung cancer diagnosis in 2019, Dan Wu first came to D. Ross Camidge, MD, PhD, at the University of Colorado Cancer Center for a second opinion.
“Dr. Camidge saved my life,” Wu said.
Patient Care Brain and Spinal Cancer Oncology Radiation
Alex Cooper relishes a challenge. Armed with a New Yorker’s moxie, an entrepreneur’s savvy, and an athlete’s determination, he has launched startups, has competed in Ironman triathlons, and offers motivational messages in blogs, videos, and social media posts as the “Iron CEO.”
Head and Neck Cancer Cancer Oncology Immunotherapy
A promising new study released by the University of Colorado Cancer Center suggests that recurrence of certain cancers can be significantly decreased by irradiating only a select set of lymph nodes near a tumor rather than all of them. |
Research Faculty Magazine Oncology
University of Colorado (CU) Cancer Center leader Wells Messersmith, MD, has been named chief medical officer of oncology services at UCHealth. In this new role, Messersmith will oversee cancer care at all UCHealth locations with a focus on expanding advanced treatments and the clinical trials UCHealth offers in partnership with the CU Cancer Center.
When it comes to cancer research the more data, the better. That is the premise behind the Oncology Research Information Exchange Network (ORIEN). The research initiative brings together 19 accomplished cancer centers to accelerate the progress of cancer research and improve clinical care.
In the field of Molecular and Cellular Oncology (MCO), cells often arrive frozen to the lab and must be thawed quickly by diluting with culture medium. And so it’s fitting that, on a macro level, molecular oncology researchers themselves arrived frozen to the 2019 MCO Retreat, held Monday at 9:00am and 4 degrees Fahrenheit on the CU Boulder campus, where they were immediately thawed with coffee.
University of Colorado Cancer Center member Dr. Steven Thorpe emphasizes the collaborative nature of treating soft tissue and bone sarcomas, highlighting the multidisciplinary efforts at CU School of Medicine's Department of Orthopedics and Children’s Hospital Colorado. He underscores the goal of not only curing the disease but also preserving function through advanced surgical techniques and modern therapies, ensuring patients maintain quality of life post-treatment. Thorpe stresses the importance of long-term outcomes, tailoring treatments to support patients’ aspirations beyond their cancer journey, especially for pediatric cases.
CU Cancer Center member S. Lindsey Davis, MD, highlighted that the combination therapy of sapanisertib and alisertib showed marginal clinical benefit for patients with advanced solid tumors, correlative analyses suggested that apoptotic response and tumor immune cell infiltrate might influence clinical outcomes. The phase 1b study's expansion cohort indicated some positive outlying responses among patients and underscore the need for further research to tailor treatments for standout patients and explore rational combinations to enhance efficacy.
A new study led by University of Colorado Cancer Center member Marco Del Chiaro, MD, PhD, reveals that nearly 5% of pancreatic adenocarcinoma patients achieved a pathological complete response (pCR) after pre-surgical chemotherapy or chemoradiotherapy. This significant finding indicates that patients with pCR have a 63% five-year survival rate, compared to 30% for those without pCR, suggesting the potential for tailored treatments to improve outcomes.
In a conversation at the 2024 European Hematology Association Congress, CU Cancer Center member Manali Kamdar, MD, discussed potential future research on lisocabtagene maraleucel (liso-cel; Breyanzi) for mantle cell lymphoma (MCL) and other lymphoma subgroups. She highlighted findings from the phase 1 TRANSCEND NHL 001 trial, noting improved efficacy and safety in patients with fewer prior therapies and non-refractory disease, suggesting liso-cel's utility in earlier treatment lines and specific lymphoma subgroups.
1665 North Aurora Court
2004
Aurora, CO 80045
720-848-0300
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.